JP2021521143A5 - - Google Patents
Info
- Publication number
- JP2021521143A5 JP2021521143A5 JP2020555310A JP2020555310A JP2021521143A5 JP 2021521143 A5 JP2021521143 A5 JP 2021521143A5 JP 2020555310 A JP2020555310 A JP 2020555310A JP 2020555310 A JP2020555310 A JP 2020555310A JP 2021521143 A5 JP2021521143 A5 JP 2021521143A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- cdr2
- cdr1
- antibody
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655417P | 2018-04-10 | 2018-04-10 | |
| US62/655,417 | 2018-04-10 | ||
| PCT/EP2019/059171 WO2019197506A1 (en) | 2018-04-10 | 2019-04-10 | Axl-specific antibodies for cancer treatment |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021521143A JP2021521143A (ja) | 2021-08-26 |
| JP2021521143A5 true JP2021521143A5 (https=) | 2022-04-18 |
| JPWO2019197506A5 JPWO2019197506A5 (https=) | 2022-04-18 |
| JP7681401B2 JP7681401B2 (ja) | 2025-05-22 |
Family
ID=66182546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555310A Active JP7681401B2 (ja) | 2018-04-10 | 2019-04-10 | がん処置のためのａｘｌ特異的抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210070869A1 (https=) |
| EP (1) | EP3774904A1 (https=) |
| JP (1) | JP7681401B2 (https=) |
| CN (1) | CN112218895A (https=) |
| AU (1) | AU2019250443A1 (https=) |
| CA (1) | CA3095986A1 (https=) |
| EA (1) | EA202092448A1 (https=) |
| IL (1) | IL277861A (https=) |
| MA (1) | MA52657A (https=) |
| WO (1) | WO2019197506A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201805534TA (en) | 2016-01-13 | 2018-07-30 | Genmab As | Formulation for antibody and drug conjugate thereof |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| WO2021013746A1 (en) * | 2019-07-19 | 2021-01-28 | Genmab A/S | Axl antibody-drug conjugates for use in treating cancer |
| CA3164706A1 (en) * | 2020-01-14 | 2021-07-22 | Jonathan David SILK | Method of treatment of cancer or tumour |
| AR121441A1 (es) * | 2020-02-28 | 2022-06-08 | Symphogen As | Anticuerpos anti-axl y composiciones |
| EP4259200A1 (en) * | 2020-12-11 | 2023-10-18 | Boehringer Ingelheim International GmbH | Formulation for multi-purpose application |
| JP2024523436A (ja) * | 2021-06-16 | 2024-06-28 | 上海▲シン▼湾生物科技有限公司 | Ａｘｌタンパク質を標的とする抗体及びその抗原結合断片、その調製方法と使用 |
| EP4359439A1 (en) | 2021-06-24 | 2024-05-01 | Yeda Research and Development Co. Ltd | Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor |
| IL289525B2 (en) * | 2021-12-30 | 2023-03-01 | B G Negev Technologies And Applications Ltd At Ben Gurion Univ | Conjugated antibodies for cancer treatment |
| WO2024178139A1 (en) * | 2023-02-22 | 2024-08-29 | Resolute Science, Inc. | Compositions and methods for targeting tumor-associated macrophages |
| WO2024178140A1 (en) * | 2023-02-22 | 2024-08-29 | Resolute Science, Inc. | Compositions and methods for targeting tumor-associated macrophages |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CA2706549A1 (en) | 2007-11-15 | 2009-05-22 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody capable of binding to anexelekto, and use thereof |
| KR20120024763A (ko) | 2009-05-15 | 2012-03-14 | 추가이 세이야쿠 가부시키가이샤 | 항ａｘｌ 항체 |
| BR112012027995A2 (pt) | 2010-06-18 | 2017-01-10 | Genentech Inc | anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl |
| CN103747803B (zh) | 2011-06-22 | 2016-10-12 | 国家医疗保健研究所 | 抗axl抗体及其用途 |
| AU2012273954A1 (en) | 2011-06-22 | 2014-01-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| WO2013090776A1 (en) | 2011-12-15 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl/gas6 signaling in the treatment of disease |
| US20160106861A1 (en) | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
| GB201410825D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| MX370807B (es) | 2014-07-11 | 2020-01-08 | Genmab As | Anticuerpos que se unen a axl. |
| JP6931609B2 (ja) * | 2014-12-18 | 2021-09-08 | ベルゲン テクノロジオーヴァーフォリング エイエス | 抗Ａｘｌアンタゴニスト抗体 |
| CN108368171A (zh) * | 2015-07-10 | 2018-08-03 | 根马布股份公司 | 用于癌症治疗的axl特异性抗体-药物缀合物 |
| WO2017146236A1 (ja) * | 2016-02-26 | 2017-08-31 | 小野薬品工業株式会社 | Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬 |
| EP3481868A1 (en) * | 2016-07-08 | 2019-05-15 | Genmab A/S | New dosage regimens for antibody drug conjugates based on anti-axl antibodies |
-
2019
- 2019-04-10 CA CA3095986A patent/CA3095986A1/en active Pending
- 2019-04-10 AU AU2019250443A patent/AU2019250443A1/en not_active Abandoned
- 2019-04-10 JP JP2020555310A patent/JP7681401B2/ja active Active
- 2019-04-10 MA MA052657A patent/MA52657A/fr unknown
- 2019-04-10 CN CN201980037687.7A patent/CN112218895A/zh active Pending
- 2019-04-10 US US17/046,199 patent/US20210070869A1/en active Pending
- 2019-04-10 EA EA202092448A patent/EA202092448A1/ru unknown
- 2019-04-10 WO PCT/EP2019/059171 patent/WO2019197506A1/en not_active Ceased
- 2019-04-10 EP EP19717837.9A patent/EP3774904A1/en active Pending
-
2020
- 2020-10-07 IL IL277861A patent/IL277861A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521143A5 (https=) | ||
| JP7550168B2 (ja) | 抗ＢＣＭＡ抗体及びγ－セクレターゼ阻害剤を使用した併用療法 | |
| CN111587124A (zh) | Ror1抗体免疫缀合物 | |
| KR102303874B1 (ko) | 항-folr1 면역접합체 투여 레지멘 | |
| JP2018525354A5 (https=) | ||
| BR112019015950A2 (pt) | conjugados de anticorpo anti-ccr7 e fármaco | |
| JP7607564B2 (ja) | Ｐｍｅｌ１７に対する抗体及びその結合体 | |
| HK1221153A1 (zh) | 抗体-药物缀合物 | |
| JP2017537893A (ja) | 抗ｃｓ１抗体および抗体薬結合体 | |
| BR112020010937A2 (pt) | anticorpos anti-liv1 humanizados para o tratamento de câncer de mama | |
| CA2858133A1 (en) | Uses of immunoconjugates targeting cd138 | |
| CA3101790A1 (en) | Anti-cd37 immunoconjugate dosing regimens | |
| CN112368020A (zh) | 抗pd-1抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法 | |
| WO2016180941A1 (en) | Liquid compositions for anti-cd19 antibody-drug conjugates | |
| JP2022541591A (ja) | がんの処置のためのヒト化抗ｌｉｖ１抗体 | |
| JP2026501556A (ja) | 抗体薬物複合体 | |
| JPWO2019197506A5 (https=) | ||
| JP2025519980A (ja) | Ｐｄ－１阻害剤またはｐｄ－ｌ１阻害剤およびクローディン１８．２を標的にする抗体－薬物コンジュゲートによるがん処置 | |
| US20230181756A1 (en) | Ccr7 antibody drug conjugates for treating cancer | |
| JP2023543026A (ja) | がんの処置のためのヒト化抗ｌｉｖ１抗体 | |
| CA2965362A1 (en) | Egfr antibody-based combination therapy | |
| AU2024298986C1 (en) | Pharmaceutical composition containing anti-nectin4 antibody-drug conjugate and anti-pd-1 antibody and use thereof | |
| WO2024208354A1 (en) | Antibody drug conjugates | |
| TW202506722A (zh) | 使用pd-1或pd-l1抑制劑及靶向密連蛋白(claudin) 18.2之抗體藥物結合物之癌症治療 | |
| HK40112252A (en) | Antibodies to pmel17 and conjugates thereof |